Martin Schröder

Dr. Martin Schröder


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMartin Schröder
Martin Schröder
MRMartin Renatus
Martin Renatus
XLXiaoyou Liang
Xiaoyou Liang
FMFabian Meili
Fabian Meili
TZThomas Zoller
Thomas Zoller
CTClaudio R. Thoma
Claudio R. Thoma
Targeted protein degradation (TPD) mediates protein level through small molecule induced redirection of E3 ligases to ubiquitinate neo-substrates and mark them for proteasomal degradation. TPD has recently emerged as a key modality in drug discovery. So far only a few ligases have been utilized for TPD. Interestingly, the workhorse ligase CRBN has been observed to be downregulated in settings of resistance to immunomodulatory inhibitory drugs (IMiDs). Here we show that the essential E3 ligase receptor DCAF1 can be harnessed for TPD utilizing a selective, non-covalent DCAF1 binder. We confirm that this binder can be functionalized into an efficient DCAF1-BRD9 PROTAC. Chemical and genetic rescue experiments validate specific degradation via the CRL4DCAF1 E3 ligase. Additionally, a dasatinib-based DCAF1 PROTAC successfully degrades cytosolic and membrane-bound tyrosine kinases. A potent and selective DCAF1-BTK-PROTAC (DBt-10) degrades BTK in cells with acquired resistance to CRBN-BTK-PROTACs while the DCAF1-BRD9 PROTAC (DBr-1) provides an alternative strategy to tackle intrinsic resistance to VHL-degrader, highlighting DCAF1-PROTACS as a promising strategy to overcome ligase mediated resistance in clinical settings.

Verified
Journal Article
Open access
PDF file
CWCarrow Wells
Carrow Wells
HAHassan Al-Ali
Hassan Al-Ali
DADavid Andrews
David Andrews
CAChristopher R. M. Asquith
Christopher R. M. Asquith
Alison Donnelly AxtmanAlison Donnelly Axtman
Alison Donnelly Axtman
David DrewryDavid Drewry
David Drewry
We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show potent kinase inhibition and a narrow spectrum of activity when screened across a large panel of kinase biochemical assays. Currently, the set contains 187 inhibitors that cover 215 human kinases. The kinase chemogenomic set (KCGS), current Version 1.0, is the most highly annotated set of selective kinase inhibitors available to researchers for use in cell-based screens.

1 May 2021 in Cell Chemical Biology
Verified
Journal Article
Closed access
BBBenedict-Tilman Berger
Benedict-Tilman Berger
MAMarta Amaral
Marta Amaral
DKDaria B. Kokh
Daria B. Kokh
Ariane Nunes-AlvesAriane Nunes-Alves
Ariane Nunes-Alves
DMDjordje Musil
Djordje Musil
SKStefan Knapp
Stefan Knapp

21 February 2022 in Molecules
Verified
Journal Article
Open access
PDF file
ATAmelie Tjaden
Amelie Tjaden
Apirat ChaikuadApirat Chaikuad
Apirat Chaikuad
EKEric Kowarz
Eric Kowarz
RMRolf Marschalek
Rolf Marschalek
SKStefan Knapp
Stefan Knapp
SMSusanne Müller
Susanne Müller
Phenotypical screening is a widely used approach in drug discovery for the identification of small molecules with cellular activities. However, functional annotation of identified hits often poses a challenge. The development of small molecules with narrow or exclusive target selectivity such as chemical probes and chemogenomic (CG) libraries, greatly diminishes this challenge, but non-specific effects caused by compound toxicity or interference with basic cellular functions still pose a problem to associate phenotypic readouts with molecular targets. Hence, each compound should ideally be comprehensively characterized regarding its effects on general cell functions. Here, we report an optimized live-cell multiplexed assay that classifies cells based on nuclear morphology, presenting an excellent indicator for cellular responses such as early apoptosis and necrosis. This basic readout in combination with the detection of other general cell damaging activities of small molecules such as changes in cytoskeletal morphology, cell cycle and mitochondrial health provides a comprehensive time-dependent characterization of the effect of small molecules on cellular health in a single experiment. The developed high-content assay offers multi-dimensional comprehensive characterization that can be used to delineate generic effects regarding cell functions and cell viability, allowing an assessment of compound suitability for subsequent detailed phenotypic and mechanistic studies.

Verified
Journal Article
Open access
PDF file
MFMichael Forster
Michael Forster
XLXiaojun Julia Liang
Xiaojun Julia Liang
MSMartin Schröder
Martin Schröder
SGStefan Gerstenecker
Stefan Gerstenecker
Apirat ChaikuadApirat Chaikuad
Apirat Chaikuad
Matthias GehringerMatthias Gehringer
Matthias Gehringer
The nonreceptor tyrosine TEC kinases are key regulators of the immune system and play a crucial role in the pathogenesis of diverse hematological malignancies. In contrast to the substantial efforts in inhibitor development for Bruton’s tyrosine kinase (BTK), specific inhibitors of the other TEC kinases, including the bone marrow tyrosine kinase on chromosome X (BMX), remain sparse. Here we present a novel class of dual BMX/BTK inhibitors, which were designed from irreversible inhibitors of Janus kinase (JAK) 3 targeting a cysteine located within the solvent-exposed front region of the ATP binding pocket. Structure-guided design exploiting the differences in the gatekeeper residues enabled the achievement of high selectivity over JAK3 and certain other kinases harboring a sterically demanding residue at this position. The most active compounds inhibited BMX and BTK with apparent IC50 values in the single digit nanomolar range or below showing moderate selectivity within the TEC family and potent cellular target engagement. These compounds represent an important first step towards selective chemical probes for the protein kinase BMX.

13 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SGStefan Gerstenecker
Stefan Gerstenecker
LHLisa Haarer
Lisa Haarer
MSMartin Schröder
Martin Schröder
MKMark Kudolo
Mark Kudolo
MSMartin Schwalm
Martin Schwalm
Matthias GehringerMatthias Gehringer
Matthias Gehringer
The ribosomal protein S6 kinase beta 2 (S6K2) is thought to play an important role in malignant cell proliferation, but is understudied compared to its closely related homolog S6 kinase beta 1 (S6K1). To better understand the biological function of S6K2, chemical probes are needed, but the high similarity between S6K2 and S6K1 makes it challenging to selectively address S6K2 with small molecules. We were able to design the first potent and highly isoform-specific S6K2 inhibitor from a known S6K1-selective inhibitor, which was merged with a covalent inhibitor engaging a cysteine located in the hinge region in the fibroblast growth factor receptor kinase (FGFR) 4 via a nucleophilic aromatic substitution (SNAr) reaction. The title compound shows a high selectivity over kinases with an equivalently positioned cysteine, as well as in a larger kinase panel. A good stability towards glutathione and Nα-acetyl lysine indicates a non-promiscuous reactivity pattern. Thus, the title compound represents an important step towards a high-quality chemical probe to study S6K2-specific signaling.